Kwality Pharmaceuticals Ltd Share Price – BSE

Pharmaceuticals, Small Cap

The company?s consolidated net profit surged 74.60% to Rs 25.30 crore in Q4 FY26, compared with Rs 14.49 crore in the same period last year.

Revenue from operations rose 35.81% YoY to Rs 157.11 crore in the quarter ended 31 March 2026.

On a sequential basis, net profit increased 58.02% and revenue grew 27.27% over Q3 FY26.

Profit before tax stood at Rs 31.67 crore in Q4 FY26, up 66.07% year-on-year and up 36.68% quarter-on-quarter.

EBITDA jumped 50.38% to Rs 38.8 crore in the March quarter, compared with Rs 25.8 crore a year earlier. EBITDA margin improved to 24.6% from 22% in the corresponding period last year.

For the full financial year FY26, the company reported a 69% surge in consolidated net profit to Rs 67.35 crore, while revenue from operations rose 35.89% to Rs 503.08 crore.

Net cash used in operating activities stood at Rs 16.59 crore in FY26 compared with positive operating cash flow of Rs 52.72 crore in FY25.

Kwality Pharmaceuticals is engaged in the business of manufacturing & trading in pharmaceuticals & allied products.

Powered by Capital Market - Live News

Net profit of Kwality Pharmaceuticals rose 74.60% to Rs 25.30 crore in the quarter ended March 2026 as against Rs 14.49 crore during the previous quarter ended March 2025. Sales rose 35.81% to Rs 157.11 crore in the quarter ended March 2026 as against Rs 115.68 crore during the previous quarter ended March 2025.

For the full year,net profit rose 69.01% to Rs 67.35 crore in the year ended March 2026 as against Rs 39.85 crore during the previous year ended March 2025. Sales rose 35.89% to Rs 503.08 crore in the year ended March 2026 as against Rs 370.20 crore during the previous year ended March 2025.

Powered by Capital Market - Live News

Kwality Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 19 May 2026.

Kwality Pharmaceuticals has received upgrade in credit ratings for bank loan facilities of the company at ICRA BBB+; Stable / ICRA A2. Further, the ratings have been removed from the ?Issuer Not Cooperating? category.